Article: Strong Ph III data for Wyeth's desvenlafaxine.(investigational drug for major depressive disorder)(Brief article)

The USA's Wyeth Pharmaceuticals presented Phase III data and results from other studies concerning its investigational drug for major depressive disorder, desvenlafaxine (DVS-233), a novel serotonin-norepinephrine reuptake inhibitor at the 2006 American Psychiatric Association Annual Meeting in Toronto, Canada, which showed significant reduction in Hamilton Depression Rating ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!